期刊文献+

螺内酯联合胺碘酮治疗阵发性心房颤动110例 被引量:6

下载PDF
导出
摘要 本研究观察螺内酯与胺碘酮联合治疗非瓣膜病阵发心房颤动的临床效果和对左心房内径大小的影响,发现螺内酯与胺碘酮联合治疗阵发性心房颤动维持窦性心律的效果优于单用胺碘酮,同时可抑制左心房结构重构并能延缓左心房的扩大,现报告如下。1资料与方法 1.1临床资料:选择2011年1月至2014年9月我院门诊及住院的非瓣膜病阵发性心房颤动患者110例,男性56例,女性54例,年龄33-85岁。
作者 张志权
出处 《中国药物与临床》 CAS 2015年第2期263-264,共2页 Chinese Remedies & Clinics
  • 相关文献

参考文献7

  • 1De Mello WC,Motta GE.The effect of aldosterene on membrane potential of cardiac muscle fibers.J Pharmacol Exp Ther,1969,167(1):166-172.
  • 2Benitah JP,Perrier E,Gomez AM,et al.Ects of aldosterone on transient outward K+current density in rat ventriculaxmyocytes[J].J Physiol,2001,537(Pt 1):151-160.
  • 3Tillmann HC,Schumacher B,Yasenyev O,et al.Acute effects of aldosterone on intracardiac monophasic action potentials[J].Int J Cardiol,2002,84(1):33-39.
  • 4Struthers AD,Mac Donald TM.Review of aldosterene-andangiotensin II induced target organ damage and prevention[J].Cardiovasc Res,2004,61(4):663-670.
  • 5Jayachandran JV,Sih HJ,Winkle W,et al.Atrial fibrillation produced by prolonged rapid atrial pacing is associated with heterogeneous changes in atrial sympathetic innervation[J].Circulation,2000,101(10):1185-1191.
  • 6姚海木,吴学思.抗肾素-血管紧张素系统研究进展[J].中国心血管病研究,2005,3(7):537-539. 被引量:4
  • 7Shi Y,Duchame A,Li D.Remodeling of artrial dimensions and empting function in canine models of atrial fibrillation[J].Calrdiovasc Res,21,52(2):217-225.

二级参考文献17

  • 1[1]Stanton A, Jensen C, Nussberger J. Blood pressure lowering in essential hypertension with an oral renin inhibitor,aliskiren. Hypertension. 2003, 42(6):1137-1143.
  • 2[2]Jafar TH, Schmid CH, Levey AS. Effect of angiotensinconverting enzyme inhibitors on progression of nondiabetic renal disease. Ann Intern Med. 2002, 137(4):298-299.
  • 3[3]Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.Lancet, 2002, 359(9311):1004-1010.
  • 4[4]Jay N, Cohn MD, Gianni T. A randomized trial of the angiotensin-receptor blocker valsartan chronic heart failure.N Engl J Med, 2001, 345(23): 1667-1675A.
  • 5[5]Scott DS, Duolao W, Peter F, et al. Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients.Circulation, 2004,110:2180-2183.
  • 6[6]Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004, 363(9426):2022-2031.
  • 7[7]David A, Scott DS, Lars K, et al. Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction. The Valsartan in Acute Myocardial Infarction (VALIANT) Trial. Circulation, 2004,110:1572-1578.
  • 8[8]Brenner BM, Cooper ME, Keane WF, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med,2001, 345(12):861-891.
  • 9[9]Ouzan J, Perault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens. 2002, 15 (4 Pt 1):333-339.
  • 10[10]Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 1999, 341 (10):709-717.

共引文献3

同被引文献43

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部